Prospective Surveillance Pilot of Rivaroxaban Safety within the US Food and Drug Administration Sentinel System

    Basic Details
    Date
    Wednesday, January 10, 2018
    Type
    Publication
    Medical Product
    rivaroxaban
    warfarin
    Health Outcome(s)
    gastrointestinal (GI) bleed
    intracranial hemorrhage
    ischemic stroke
    Description

    The U.S. Food and Drug Administration's Sentinel System developed tools for sequential surveillance. This tool was used to sequentially compare outcomes for new users of rivaroxaban versus warfarin, employing propensity score matching and Cox regression. This study demonstrates the capability of Sentinel to conduct prospective safety monitoring and raises no new concerns about rivaroxaban safety.

    Author(s)

    Elizabeth A. Chrischilles PhD, MS; Joshua J. Gagne PharmD, ScD; Bruce Fireman MA; Jennifer Nelson PhD; Sengwee Toh ScD; Azadeh Shoaibi PhD, MHS; Marsha E. Reichman PhD; Shirley Wang PhD, ScM; Michael Nguyen MD; Rongmei Zhang PhD; Rima Izem PhD; Margie R. Goulding PhD; Mary Ross Southworth PharmD; David J. Graham MD, MPH; Candace Fuller PhD; Hannah Katcoff MPH; Tiffany Woodworth MPH; Catherine Rogers MPH; Ryan Saliga BBA; Nancy D. Lin ScD; Cheryl N. McMahill-Walraven PhD, MSW; Vinit P. Nair BPharm, MS, RPh; Kevin Haynes PharmD, MSCE; Ryan M. Carnahan PharmD, MS, BCPP

    Corresponding Author

    E. Chrischilles, Department of Epidemiology, College of Public Health, University of Iowa, 145 N. Riverside Dr., Iowa City, IA 52242-2007, USA. Email: e-chrischilles@uiowa.edu